Clorox (CLX) Q4 Earnings and Revenues Top Estimates

Clorox (CLX) reported robust Q4 earnings, with EPS of $2.87 significantly exceeding the Zacks Consensus Estimate of $2.24 and revenues reaching $1.99 billion, surpassing expectations by 3.04%. Despite these beats, the stock has substantially underperformed the market year-to-date, declining 22.3% against the S&P 500's 8.2% gain. The company's future outlook is tempered by an unfavorable estimate revision trend, resulting in a Zacks Rank #5 (Strong Sell), indicating potential near-term underperformance.

Analysis

Clorox (CLX) reported a notable performance in its fourth quarter, with adjusted EPS of $2.87 significantly exceeding the Zacks Consensus Estimate of $2.24 by 28.12% and showing substantial growth from $1.82 a year ago. Revenues also modestly surpassed expectations, coming in at $1.99 billion, a 3.04% beat. Despite this strong quarterly report and a track record of beating consensus estimates three times in the last four quarters, the company's stock presents a conflicting picture. It has severely underperformed the broader market, declining 22.3% year-to-date against the S&P 500's 8.2% gain. This disconnect is largely explained by a pessimistic forward-looking outlook, underscored by an unfavorable trend in earnings estimate revisions leading into the report. Consequently, the stock currently holds a Zacks Rank #5 (Strong Sell), indicating a strong expectation of near-term underperformance that outweighs the positive historical results. The sustainability of any positive momentum will hinge on management's forward guidance and subsequent analyst estimate revisions.

Key Decisions for Investors

• Investors should treat the strong Q4 earnings beat with caution, as it is contradicted by the stock's significant year-to-date underperformance and a highly pessimistic analyst rating.
• The Zacks Rank #5 (Strong Sell) signals a potent headwind, suggesting that holding or initiating a long position carries substantial near-term risk of further underperformance relative to the market.
• Closely monitor management's commentary from the earnings call and any subsequent changes to forward earnings estimates, as these will be the primary catalysts to either validate or reverse the current bearish outlook.